The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases
- 1 September 2014
- journal article
- review article
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 42, 103-129
Abstract
No abstract availableKeywords
This publication has 265 references indexed in Scilit:
- VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models of Experimental GlaucomaThe American Journal of Pathology, 2013
- Inflammation in diabetic retinopathyProgress in Retinal and Eye Research, 2011
- Animal models of choroidal and retinal neovascularizationProgress in Retinal and Eye Research, 2010
- Effects of insulin-like growth factor-1 (IGF-1) receptor signaling on rates of apoptosis in retina of dopamine beta hydroxylase (Dbh−/−) knockout miceAutonomic Neuroscience, 2010
- The neurovascular retina in retinopathy of prematurityProgress in Retinal and Eye Research, 2009
- Analysis of full and partial agonists binding toβ2‐adrenergic receptor suggests a role of transmembrane helix V in agonist‐specific conformational changesJournal of Molecular Recognition, 2009
- Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cellsMicrovascular Research, 2009
- Infantile Hemangiomas: An Emerging Health Issue Linked to an Increased Rate of Low Birth Weight InfantsThe Journal of Pediatrics, 2008
- Neovascular glaucomaProgress in Retinal and Eye Research, 2007
- Induction of nerve growth factor and basic fibroblast growth factor mRNA following clenbuterol: Contrasting anatomical and cellular localizationExperimental Neurology, 1995